Compare MNPR & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNPR | VINP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 601.4M |
| IPO Year | 2019 | 2020 |
| Metric | MNPR | VINP |
|---|---|---|
| Price | $70.28 | $8.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $130.17 | $12.24 |
| AVG Volume (30 Days) | 127.0K | ★ 133.5K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 8.27% |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.39 |
| Revenue Next Year | N/A | $11.29 |
| P/E Ratio | ★ N/A | $24.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $50.07 | $8.10 |
| 52 Week High | $124.82 | $13.61 |
| Indicator | MNPR | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 32.70 |
| Support Level | $66.88 | N/A |
| Resistance Level | $75.33 | $10.17 |
| Average True Range (ATR) | 4.74 | 0.43 |
| MACD | 0.73 | -0.03 |
| Stochastic Oscillator | 51.81 | 10.00 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.